Merck Announces Agreement to Acquire Alydia Health Before Spinoff of Organon
March 30, 2021
New York – Paul Hastings LLP, a leading global law firm, announced today that the firm advised Merck, known as MSD outside the United States and Canada, on a definitive agreement with Alydia Health, a commercial-stage medical device company focused on preventing maternal morbidity and mortality.
Under the terms of the agreement, Alydia will be acquired by Organon after the planned spinoff of the organization for up to $240 million total consideration, including $215 million upfront plus a $25 million contingent milestone payment.
The deal is subject to customary closing conditions and completion of Organon's spinoff from Merck, currently scheduled in the second quarter of 2021.
The Paul Hastings team was led by M&A partner David Shine, and included partners Eric Keller, Chuck Patrizia, Todd Schneider, attorney Jason Hill, and associates Robert Dixon, Kyndle Bennett, and Ryan Enchelmayer.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.